These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. [Comparison of adenosine versus iloprost by acute vasodilator test in patients of pulmonary arterial hypertension complicated with connective tissue diseases]. Tian Z; Chen TB; Fang Q; Zeng XF; Liu YT; Li MT; Jiang XC; Gao P; Cheng KA; Wang Q Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(30):2099-102. PubMed ID: 20058611 [TBL] [Abstract][Full Text] [Related]
26. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. McLaughlin VV Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005 [TBL] [Abstract][Full Text] [Related]
27. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses. Karavolias GK; Georgiadou P; Gkouziouta A; Kariofillis P; Karabela G; Tsiapras D; Sbarouni E; Chaidaroglou A; Degiannis D; Adamopoulos S; Voudris V Expert Opin Ther Targets; 2010 Dec; 14(12):1283-9. PubMed ID: 20958219 [TBL] [Abstract][Full Text] [Related]
28. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355 [TBL] [Abstract][Full Text] [Related]
29. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Hachulla E; de Groote P; Gressin V; Sibilia J; Diot E; Carpentier P; Mouthon L; Hatron PY; Jego P; Allanore Y; Tiev KP; Agard C; Cosnes A; Cirstea D; Constans J; Farge D; Viallard JF; Harle JR; Patat F; Imbert B; Kahan A; Cabane J; Clerson P; Guillevin L; Humbert M; Arthritis Rheum; 2009 Jun; 60(6):1831-9. PubMed ID: 19479881 [TBL] [Abstract][Full Text] [Related]
30. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127 [TBL] [Abstract][Full Text] [Related]
32. The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension. Mukerjee D; Yap LB; Ong V; Denton CP; Howells K; Black CM; Coghlan JG Ann Rheum Dis; 2004 Dec; 63(12):1627-31. PubMed ID: 15547087 [TBL] [Abstract][Full Text] [Related]
33. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. McLaughlin V; Humbert M; Coghlan G; Nash P; Steen V Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219 [TBL] [Abstract][Full Text] [Related]
34. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007 [TBL] [Abstract][Full Text] [Related]
35. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050 [TBL] [Abstract][Full Text] [Related]
36. Bosentan therapy for pulmonary arterial hypertension. Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289 [TBL] [Abstract][Full Text] [Related]
37. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension. Kähler CM; Graziadei I; Wiedermann CJ; Kneussl MP; Vogel W Wien Klin Wochenschr; 2000 Jul; 112(14):637-40. PubMed ID: 11008327 [TBL] [Abstract][Full Text] [Related]
38. Predicting the Need for Upfront Combination Therapy in Pulmonary Arterial Hypertension. Bajwa AA; Qureshi T; Shujaat A; Seeram V; Jones LM; Al-Saffar F; Cury JD J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):395-400. PubMed ID: 25613465 [TBL] [Abstract][Full Text] [Related]
39. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease. Durongpisitkul K; Jakrapanichakul D; Sompradikul S J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984 [TBL] [Abstract][Full Text] [Related]